Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
10,783
datasets available to search
ShareScore release 0.9.0
Dataset results
10,783 results for “Pharmacokinetics”
A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)
ClinicalTrials.gov study NCT03268941. IPD Sharing: YES. Countries: 1. Publications: 1.
A Trial to Evaluate the Effect of the Proton Pump Inhibitor Esomeprazole on the Single-dose Pharmacokinetics (PK) of Oral TAK-906 in Healthy Adult Participants
ClinicalTrials.gov study NCT03849690. IPD Sharing: YES. Countries: 1. Publications: 1.
Safety, Tolerability, Pharmacokinetic, and Efficacy Study of SPD489 in Preschool Children With Attention-deficit/Hyperactivity Disorder
ClinicalTrials.gov study NCT02402166. IPD Sharing: YES. Countries: 1. Publications: 1.
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabraf
ClinicalTrials.gov study NCT02124772. IPD Sharing: YES. Countries: 5. Publications: 3.
Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria
ClinicalTrials.gov study NCT04300309. IPD Sharing: YES. Countries: 2. Publications: 1.
Effects of Ledipasvir/Sofosbuvir on the Pharmacokinetics and Renal Safety of Tenofovir Alafenamide (TAF)
ClinicalTrials.gov study NCT03126370. IPD Sharing: NO. Countries: 1. Publications: 20.
Efficacy, Safety and Pharmacokinetics of Teriflunomide in Pediatric Patients With Relapsing Forms of Multiple Sclerosis
ClinicalTrials.gov study NCT02201108. IPD Sharing: YES. Countries: 22. Publications: 3.
Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.
ClinicalTrials.gov study NCT03610516. IPD Sharing: YES. Countries: 10. Publications: 1.
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r)
ClinicalTrials.gov study NCT03439280. IPD Sharing: YES. Countries: 1. Publications: 1.
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
ClinicalTrials.gov study NCT03291288. IPD Sharing: YES. Countries: 4. Publications: 1.
A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety of Venglustat in Late-onset GM2
ClinicalTrials.gov study NCT04221451. IPD Sharing: YES. Countries: 13. Publications: 1.
Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria
ClinicalTrials.gov study NCT03896152. IPD Sharing: YES. Countries: 4. Publications: 1.
Comparison of physiologically based pharmacokinetic modeling platforms for developmental neurotoxicity in vitro to in vivo extrapolation
Open the record for dataset details and reuse information.
Data from: In vitro to in vivo extrapolation from three-dimensional hiPSC-derived cardiac microtissues and physiologically based pharmacokinetic modeling to inform next-generation arrythmia risk assessment
Open the record for dataset details and reuse information.
Pharmacodynamics parameters underlying the manuscript: The effect of morning versus evening administration of empagliflozin on its pharmacokinetics and pharmacodynamics characteristics in healthy adults: a two-way crossover, non-randomised trial
<p><b>Background</b>: Empagliflozin is an SGLT2 inhibitor approved for use in patients with Diabetes Mellitus type 2 (DMT2) with- or without other cardiovascular disease. Empagliflozin is taken once daily without rationale on the optimal timing for administration. This study aimed<b> </b>to determine the chronopharmacological effects of morning vs evening administration of empagliflozin 10 mg in Healthy Egyptian adults, by investigating the pharmacokinetics and pharmacodynamics parameters of empagliflozin depending on the intake time. </p> <p><b>Methods: </b>An open label, sequential, two‐way crossover trial comprised two periods with a washout period of 7 days. Pharmacokinetics parameters (t<sub>max</sub> (h), C<sub>max</sub> (ng/ml), AUC <sub>0-t</sub> (ng.h/ml)) as primary endpoints, and (AUC <sub>0 to ∞</sub>(ng.h/ml)) as secondary endpoint were assessed. Method validation was done prior to injection in LC/MS/MS and samples were processed by Liquid-Liquid extraction. The pharmacodynamic profile (UGE <sub>0-24</sub>) was determined after method validation (glucose hexokinase method).</p> <p><b>Results: </b>T<sub>max</sub> increased by (35%) in the evening phase compared to the morning phase, while C<sub>max</sub> decreased by (-6.5%)in the evening dose compared to the morning dose. Besides, AUC<sub>0 to ∞</sub> increased in the evening phase by (8.25%) compared to the morning phase. The mean cumulative amount of glucose excreted; UGE (<sub>0-24</sub>) increased by (43%) in the evening dose compared to the morning dose</p> <p><strong>Conclusion: </strong>Despite there was a significant difference between morning and evening doses, it didn't reach the significant level, thus, it can be concluded that there is no difference between the morning and evening doses.</p>
Dataset belonging to SNF project: Use of physiologically based pharmacokinetic modelling to simulate dosing requirements of long-acting intramuscular antiretroviral drugs in special populations and to manage drug-drug interactions
Open the record for dataset details and reuse information.
Figure 1. Kaempferol-3-O in Analysis of the toxicological and pharmacokinetic profile of Kaempferol-3-O-β-D-(6"-E-p-coumaryl) glucopyranoside - Tiliroside: in silico, in vitro and ex vivo assay
Figure 1. Kaempferol-3-O-β-D-(6"-E-p-coumaryl) glucopyranoside – tiliroside.
Pharmacokinetic data for CYP3A4 probe substrates in healthy Humans.
<p>This dataset contains all extracted informations used in the article "Inter-ethnic differences in CYP3A4 metabolism: A Bayesian meta-analysis for the refinement of uncertainty factors in chemical risk assessment" (<a href="https://doi.org/10.1016/j.comtox.2019.100092">https://doi.org/10.1016/j.comtox.2019.100092</a>).</p>
Impact of CYP3A5 Genotypes on Tacrolimus Pharmacokinetics in Colombian Liver Transplant Patients
<p><strong><span>Impact of CYP3A5 Genotypes on Tacrolimus Pharmacokinetics in Colombian Liver Transplant Patients</span></strong></p>
Pharmacokinetic dataset of a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19
<p>Abstract</p> <p>Background</p> <p>The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in the lungs. Although there is no proven therapy to reduce pulmonary vascular leak in ARDS, recent studies demonstrated that the tyrosine kinase inhibitor imatinib reinforces the endothelial barrier and prevents vascular leak in inflammatory conditions, while leaving the immune response intact.</p> <p>Methods</p> <p>This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter clinical trial of intravenous (IV) imatinib mesylate in 90 mechanically ventilated subjects with COVID-19-induced ARDS. Subjects are 18 years or older, admitted to the ICU for mechanical ventilation, meeting the Berlin criteria for moderate-severe ARDS with a positive polymerase chain reaction test for SARS-CoV2. Participants will be randomized in a 1:1 ratio to either imatinib (as mesylate) 200 mg bis in die (b.i.d.) or placebo IV infusion for 7 days, or until ICU discharge or death. The primary study outcome is the change in Extravascular Lung Water Index (EVLWi) between day 1 and day 4. Secondary outcome parameters include changes in oxygenation and ventilation parameters, duration of invasive mechanical ventilation, number of ventilator-free days during the 28-day study period, length of ICU stay, and mortality during 28 days after randomization. Additional secondary parameters include safety, tolerability, and pharmacokinetics.</p> <p>Discussion</p> <p>The current study aims to investigate the efficacy and safety of IV imatinib in mechanically ventilated subjects with COVID-19-related ARDS. We hypothesize that imatinib decreases pulmonary edema, as measured by extravascular lung water using a PiCCO catheter. The reduction in pulmonary edema may reverse hypoxemic respiratory failure and hasten recovery. As pulmonary edema is an important contributor to ARDS, we further hypothesize that imatinib reduces disease severity, reflected by a reduction in 28-day mortality, duration of mechanical ventilation, and ICU length of stay.</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.